title: [IL-2 gene and cisplatin combined therapy for head and neck squamous cell carcinoma].
abstract: OBJECTIVE
  The objective of this study is to assess the efficacy of IL-2 gene and cisplatin combined therapy on murine HNSCC models.
  
  
  METHODS
  HNSCC tumors were established in murine models. The sizes of tumors were measured before and after combined IL-2 and cisplatin treatment, and the results were evaluated by comparing different single treatment groups and the control IL-2 expression was measured after IL-2 gene transfer. Cytotoxic T-lymphocyte (CTL) and natural killer (NK) assays were also performed.
  
  
  RESULTS
  HNSCC tumor growth was significantly inhibited following combined IL-2 gene and cisplatin therapy, when compared with that of the control. The levels of IL-2 protein expressions were increased in combined and single IL-2 treated groups. The activities of cytotoxic T-lymphocytes and natural killers in both the combined treatment group and the IL-2 treated group are higher than those of the controlled group.
  
  
  CONCLUSIONS
  Combined IL-2 gene and cisplatin therapy can significantly inhibit HNSCC tumor growth in the murine models, and efficiently induces anti-tumor immune reaction of hosts.
authors.affiliation: Department of Otolaryngology, First Affiliated Hospital, West China University of Medical Sciences.
authors.forename: S
authors.initials: S
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Lin
authors.forename: S
authors.initials: S
authors.lastname: Tang
authors.forename: H
authors.initials: H
authors.lastname: Yang
authors.forename: C
authors.initials: C
authors.lastname: Liang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000628:therapy*; D007376:Interleukin-2 / Q000235:genetics*; D007694:Killer Cells, Natural / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D002945:Cisplatin